ProKidney Analyst Ratings
J.P. Morgan Initiates ProKidney(PROK.US) With Hold Rating
ProKidney Initiated at Buy by Guggenheim
Guggenheim Initiates Coverage On ProKidney With Buy Rating, Announces Price Target of $6
Guggenheim Initiates ProKidney(PROK.US) With Buy Rating, Announces Target Price $6
Buy Rating on ProKidney: Promising Prospects in Chronic Kidney Disease Treatment
Morgan Stanley Maintains ProKidney(PROK.US) With Hold Rating, Maintains Target Price $3
BofA Securities Maintains ProKidney(PROK.US) With Hold Rating, Maintains Target Price $3
Morgan Stanley Maintains ProKidney(PROK.US) With Hold Rating, Maintains Target Price $3
ProKidney Is Maintained at Neutral by B of A Securities
ProKidney Analyst Ratings
BofA Securities Maintains ProKidney(PROK.US) With Hold Rating, Cuts Target Price to $3
Morgan Stanley Maintains ProKidney(PROK.US) With Hold Rating, Maintains Target Price $3
Maintaining Hold on ProKidney Amid Strategic Shifts and Regulatory Uncertainties
ProKidney's Hold Rating Maintained Amid Financing and Clinical Uncertainties
BTIG Maintains ProKidney(PROK.US) With Buy Rating, Maintains Target Price $5
ProKidney Analyst Ratings
Jefferies Maintains Buy on ProKidney, Lowers Price Target to $6
ProKidney Analyst Ratings
Buy Rating Affirmed for ProKidney on Rilparencel's Promising Efficacy in CKD Treatment
No Data
No Data